Artravir^®-Inkamfarm (Ointment) Instructions for Use

Marketing Authorization Holder

Incampharm, LLC (Russia)

Manufactured By

Biokhimik, JSC (Russia)

ATC Code

M01AX25 (Chondroitin sulfate)

Active Substance

Chondroitin sulfate sodium (Ph.Eur.)

Dosage Form

Artravir®-Inkampharm®

Ointment for external use 5%: tubes 10 g, 15 g, 20 g, 25 g, 30 g, 50 g, 75 g or 100 g; jars 25 g or 50 g

Dosage Form, Packaging, and Composition

Ointment for external use is light yellow in color with a characteristic odor.

Excipients: dimethyl sulfoxide – 10 g, anhydrous lanolin – 15 g, medical petrolatum – 50 g, purified water – up to 100 g.

10 g – aluminum tubes (1) – cardboard packs.
15 g – aluminum tubes (1) – cardboard packs.
20 g – aluminum tubes (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.
75 g – aluminum tubes (1) – cardboard packs.
100 g – aluminum tubes (1) – cardboard packs.
25 g – glass jars (1) – cardboard packs.
50 g – glass jars (1) – cardboard packs.

Clinical-Pharmacological Group

Drug with cartilage tissue regeneration improving and anti-inflammatory action for external use

Pharmacotherapeutic Group

Tissue repair stimulant

Pharmacological Action

The agent affects phosphorus-calcium metabolism in cartilage tissue and is a high molecular weight mucopolysaccharide. It has chondrostimulating, regenerating, anti-inflammatory, and analgesic effects. Chondroitin sulfate is involved in the construction of the fundamental substance of cartilage and bone tissue.

It possesses chondroprotective properties, enhances metabolic processes in hyaline and fibrous cartilage, and subchondral bone; inhibits enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of proteoglycans by chondrocytes.

It helps reduce the release of inflammatory mediators and pain factors into the synovial fluid, suppresses the secretion of leukotrienes and prostaglandins. It slows down bone tissue resorption and reduces calcium loss, accelerates bone tissue repair processes. Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis.

It promotes the restoration of the joint capsule and cartilaginous joint surfaces, prevents the collapse of connective tissue, and normalizes the production of synovial fluid.

When applied externally, it slows the progression of osteoarthritis. It normalizes metabolism in hyaline tissue. It stimulates the regeneration of articular cartilage.

Pharmacokinetics

Chondroitin sulfate, after application to the skin, quickly and selectively penetrates into joint tissues, reaching C_max within 30 minutes, followed by biphasic elimination from the cartilage tissue. The completion of the rapid elimination phase occurs 1 hour after application. The retention time in the joint is 5 hours.

Indications

Degenerative-dystrophic diseases of the joints and spine (osteoarthritis of peripheral joints, intervertebral osteoarthrosis, and osteochondrosis).

ICD codes

Dosage Regimen

Apply the ointment externally to the affected joint or spinal area two to three times daily.

Use a sufficient amount to cover the entire painful area with a thin, uniform layer.

Gently rub the ointment into the skin until fully absorbed.

The standard treatment course is two to three weeks.

Depending on the clinical response, the course may be repeated as advised by a physician.

Avoid applying the ointment to damaged skin, open wounds, or mucous membranes.

Wash hands thoroughly with soap and water after each application.

Do not cover the application site with occlusive dressings unless specifically directed.

If no improvement is observed after two weeks of use, or if symptoms worsen, discontinue use and consult a doctor.

Do not exceed the recommended frequency or duration of application.

Adverse Reactions

Allergic reactions infrequently – skin itching, erythema, urticaria.

Contraindications

Hypersensitivity to chondroitin sulfate.

With caution

Pregnancy, breastfeeding period, childhood and adolescence under 18 years.

Use in Pregnancy and Lactation

Use with caution during pregnancy and breastfeeding.

Pediatric Use

Use with caution in children and adolescents under 18 years of age.

Geriatric Use

There are no specific instructions for use in elderly patients.

Special Precautions

In case of allergic reactions or hemorrhages, treatment should be discontinued.

Storage Conditions

Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.